Evidence map›Paper›PMID 31368050›Full record

ReviewJournal of endocrinological investigation2020

Copeptin in the differential diagnosis of hypotonic polyuria.

M Christ-Crain, W K Fenske

Abstract readReview
PubMed Publisher
In one paragraph

Review in Journal of endocrinological investigation, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.6field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 21 citations in OpenAlex.

  1. Copeptin in the diagnosis and management of renal tubular disorders.Pediatric nephrology (Berlin, Germany) · 2026
    Review
  2. Article
  3. Article
  4. Article
  5. A New Biomarker Copeptin in Determining Disease Severity in COVID-19.Infectious diseases & clinical microbiology · 2024
    Article
  6. Article
  7. Article
  8. Urinary symptoms: broadening the horizons for the copeptin assay.Journal of endocrinological investigation · 2020
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

M Christ-CrainDepartment of Endocrinology, Diabetology and Metabolism, University Hospital of Basel, University of Basel, Petersgraben 4, 4031, Basel, Switzerland. mirjam.christ-crain@unibas.ch.
W K FenskeDepartment of Endocrinology, Diabetology and Metabolism, University Hospital of Basel, University of Basel, Petersgraben 4, 4031, Basel, Switzerland. WiebkeKristin.Fenske@medizin.uni-leipzig.de.
University Hospital of Basel · CHUniversity of Basel · CH

Funding

Swiss National Funding SNF-162608
6 · The paper itself

Abstract

copeptinCopeptin is secreted in equimolar amount to Arginine Vasopressin (AVP) but can easily be measured with a sandwich immunoassay. Both peptides, copeptin and AVP, show a high correlation. Accordingly, copeptin mirrors the amount of AVP in the circulation and its measurement provides an attractive marker in the differential diagnosis of diabetes insipidus. THE POLYURIA POLYDIPSIA SYNDROME: Diabetes insipidus-either central or nephrogenic-has to be differentiated from primary polydipsia. Differentiation is crucial since wrong treatment can have deleterious consequences. Since many decades, the "gold standard" for differential diagnosis has been the classical water deprivation test, which has several limitations leading to an overall limited diagnostic accuracy. In addition, the test has a long duration of 17 hours and is cumbersome for patients. Clinical signs and symptoms as well as MRI characteristics overlap between patients with diabetes insipidus and primary polydipsia. Direct measurement of AVP upon osmotic stimulation was first shown to overcome these limitations, but failed to enter clinical practice mainly due to technical limitations of the AVP assay. COPEPTIN AS DIAGNOSTIC TOOL IN THE POLYURIA POLYDIPSIA SYNDROME: We have recently shown that copeptin, without prior water deprivation, identifies patients with nephrogenic diabetes insipidus. On the other hand, for the more difficult differentiation between central diabetes insipidus and primary polydipsia, a copeptin level of 4.9 pmol/L stimulated with hypertonic saline infusion differentiates between these two entities with a high diagnostic accuracy, and is superior to the water deprivation test. It is important to note that close sodium monitoring during the hypertonic saline test is a prerequisite.

conclusionTherefore, we propose that copeptin upon hypertonic saline infusion should become the new standard test in the differential diagnosis of diabetes insipidus.

Indexed as

BiomarkersDiagnosis, DifferentialGlycopeptidesHumansPolyuriaBiomarkerscopeptinsGlycopeptidesDiabetes insipidusDifferential diagnosisPrimary polydipsia

Identifiers

PMID31368050
OpenAlexW2966417896

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.